Ann Arbor, MINCT07144163Now EnrollingIRB Ready

Congenital Adrenal Hyperplasia Clinical Trial in Ann Arbor, MI

Access cutting-edge congenital adrenal hyperplasia treatment through this clinical trial at a research site in Ann Arbor. Study-provided care at no cost to qualified participants.

Sponsored by Crinetics Pharmaceuticals Inc.

Quick Self-Assessment

See if you qualify for this Ann Arbor location

Preparing your pre-screening questions…

Expert Care in Ann Arbor

Access congenital adrenal hyperplasia specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related congenital adrenal hyperplasia treatment provided free

Apply for This Ann Arbor Location

Check if you qualify for this congenital adrenal hyperplasia clinical trial in Ann Arbor, MI

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Ann Arbor

    Convenient for MI residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Ann Arbor site if eligible
  4. 4Begin participation

About This Congenital Adrenal Hyperplasia Study in Ann Arbor

The purpose of this study is to evaluate the efficacy, safety, PK, and PD of atumelnant in adults with classic CAH due to 21-OHD.

Sponsor: Crinetics Pharmaceuticals Inc.

Who Can Participate

Inclusion Criteria

Male or female, between ≥18 to \<75 years of age at the time of signing the ICF.
Willing and able to understand and adhere to the study procedures as specified in the protocol and comply with the study treatment.
Have classic CAH due to 21-OHD confirmed by the Investigator.
Participants with Visit 2 levels of morning serum A4 as follows:
A4 \>ULN and treated with \<11 mg/m2/day (physiologic) GC doses
OR normal A4 (\>0.5xULN to ≤1xULN) and treated with ≥14 mg/m2/day GC doses
OR A4 \>ULN and treated with ≥11 mg/m2/day GC doses.
On a stable (defined as no dose change of \>5 mg/day hydrocortisone equivalent within 2 months prior to Screening) regimen of GC replacement (e.g., hydrocortisone, prednisolone, prednisone, methylprednisolone, meprednisone, dexamethasone, cortisone acetate) at the time of informed consent.
If treated with mineralocorticoids (fludrocortisone), the dose should be stable for at least 1 month prior to Screening without orthostatic hypotension, and with serum sodium and potassium in the normal range.
If on estrogen therapy (any route), the dose must be stable for at least 3 months prior to Screening.

Exclusion Criteria

Diagnosis of any form of CAH other than classic 21-OHD.
History of bilateral adrenalectomy, hypopituitarism, or other condition requiring chronic GC therapy.
Clinically significant medical condition or abnormal laboratory tests, as judged by the Investigator, other than CAH.
Concomitant mental condition rendering him/her unable to understand the nature, scope, and possible consequences of the study, and/or evidence of poor compliance with medical instructions.
History of cancer excluding cured/treated dermal squamous or basal cell carcinoma or cervical carcinoma in situ.
Women who are pregnant or lactating or, if of childbearing potential, who are unwilling to use highly effective contraception as described in this study. Male participants who are unwilling to use highly effective contraception as described in this study.
Known history of, or concern for, risk of hypersensitivity reaction to atumelnant or any of its excipients.
Participants with an increased risk of developing adrenal insufficiency as judged by the Investigator.
Severe erythrocytosis as judged by the Investigator.
Use of atumelnant prior to screening.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Ann Arbor?

Yes, this clinical trial (NCT07144163) has an active research site in Ann Arbor, MI that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Congenital Adrenal Hyperplasia Treatment Options in Ann Arbor, MI

If you're searching for congenital adrenal hyperplasia treatment options in Ann Arbor, MI, this clinical trial (NCT07144163) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Ann Arbor research site is actively enrolling participants for this clinical trial. You'll receive care from experienced congenital adrenal hyperplasia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all congenital adrenal hyperplasia clinical trials near you to find additional studies recruiting in your area.

More Pulmonary Embolism Trials in Ann Arbor, MI

See all pulmonary embolism clinical trials recruiting in Ann Arbor — not just this study.

Browse Pulmonary Embolism Trials in Ann Arbor →

Browse More Trials by Condition

Pulmonary Embolism TrialsAlzheimers Disease TrialsAnkylosing Spondylitis TrialsAtopic Dermatitis TrialsRetinitis Pigmentosa TrialsRecurrent Pregnancy Loss TrialsAll Conditions →

Ready to Join in Ann Arbor?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Ann Arbor, MI